The Leuven experience with a dichotomy in Bronchiolitis Obliterans Syndrome (BOS) after lung transplantation revealed by azithromycin

B Vanaudenaerde, R Vos, N Geudens… - European …, 2008 - Eur Respiratory Soc
BOS is the most important cause of late mortality after LTx. Until 5 years ago, the prevalence
was around 30% and 50%, 3 and 5 years after LTx. Introduction of azithromycin (AZI) …

206: A Retrospective Analysis of Long-Term Azithromycin Therapy for Bronchiolitis Obliterans Syndrome after Lung Transplantation

BM Vanaudenaerde, R Vos, A Ottevaere… - The Journal of Heart …, 2009 - jhltonline.org
Purpose BOS is the most important cause of late mortality after LTx and is characterized by a
neutrophilic inflammatory process leading to fibroproliferation and an irreversible decline in …

A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy

BM Vanaudenaerde, I Meyts, R Vos… - European …, 2008 - Eur Respiratory Soc
Bronchiolitis obliterans syndrome (BOS) is the most important cause of late mortality
following lung transplantation, resulting in major morbidity and a huge burden on healthcare …

Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal?

GM Verleden, LJ Dupont… - European Respiratory …, 2005 - Eur Respiratory Soc
Chronic rejection (obliterative bronchiolitis) is the single most important cause of chronic
allograft dysfunction and late mortality after lung transplantation. As this condition is difficult …

A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation.

SS Ladak - Breathe, 2015 - search.ebscohost.com
Lung transplantation has proved to be successful in carefully selected individuals suffering
from end stage lung diseases. However, post-lung transplant long-term graft survival is …

A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation

P Corris, T Small, V Ryan, J Lordan… - D13. SCIENTIFIC …, 2012 - atsjournals.org
METHODS. A prospective, single-centre randomised double blind placebo controlled study
of Azithromycin (250mg on alternate days) or placebo, in lung transplant recipients with …

Bronchiectasis as prognostic factor in bronchiolitis obliterans syndrome after lung transplantation

A Van Herck, A Sacreas, T Heigl, S Verleden… - 2018 - Eur Respiratory Soc
Long-term survival after lung transplantation (LTx) is hampered by chronic lung allograft
dysfunction, with bronchiolitis obliterans syndrome (BOS) as its most common phenotype …

Obliterative bronchiolitis following lung transplantation: from old to new concepts?

GM Verleden, R Vos, SI De Vleeschauwer… - Transplant …, 2009 - Wiley Online Library
Lung transplantation has come of age and is now considered a valid treatment for selected
patients with end‐stage lung disease. In recent years, survival rates have much improved …

[HTML][HTML] Markers of bronchiolitis obliterans syndrome after lung transplant: between old knowledge and future perspective

D Cavallaro, M Guerrieri, S Cattelan, G Fabbri, S Croce… - Biomedicines, 2022 - mdpi.com
Bronchiolitis obliterans syndrome (BOS) is the most common form of CLAD and is
characterized by airflow limitation and an obstructive spirometric pattern without high …

Bronchiolitis Obliterans Syndrome and Restrictive Allograft Syndrome: Do Specific Risk Factors Differ?

SE Verleden, D Ruttens, E Vandermeulen… - The Journal of Heart …, 2013 - jhltonline.org
Purpose Chronic rejection is one of the major problems hampering long-term survival after
lung transplantation (LTx). Recently, it became clear that patients with an irreversible decline …